April 30, 2026
Company name: Mitsubishi Chemical Group Corporation Representative: Manabu Chikumoto
Representative Corporate Executive Officer, President and Chief Executive Officer Listed on the Prime Market of TSE (stock code: 4188
Contact: [Press inquiries]
Corporate Communications Office Tel: (+81) (0)3-6748-7140
[IR inquiries]
Investor Relations Office Tel: (+81) (0)3-6748-7120
Notice Regarding Changes in Specified SubsidiariesMitsubishi Chemical Group Corporation (hereinafter "MCG") hereby announces that there has been a change in our specified subsidiary as detailed below.
-
Reason for the Change
Nippon Sanso Holdings Corporation (TSE Prime: 4091; Head office: Shinagawa-ku, Tokyo; Representative Director, President CEO: Toshihiko Hamada; hereinafter "NSHD"), a consolidated subsidiary of MCG, reached an agreement to acquire Esteve Teijin Healthcare, S.L., which was under Corporación Químico-Farmacéutica Esteve and Teijin Holdings Europe B.V. and operates home healthcare services business in Spain. The acquisition was made through Oximesa S.L.U., the Spanish subsidiary of its European subsidiary, Nippon Sanso Euro-Holding S.L.U. (formerly Nippon Gases Euro-Holding S.L.U.).
On March 3, 2026, NSHD completed the procedures to acquire the shares of the target company based on this agreement and subsequently renamed the acquired company to "Nippon Sanso Homecare España, S.L.U.". After acquiring the shares of the company and making it a subsidiary, NSHD conducted a review of the company's past capital transactions and it has been determined that Nippon Sanso Homecare España, S.L.U., which became a consolidated subsidiary, has become MCG's specified subsidiary because its capital corresponds to an amount equivalent to 10% or more of MCG's capital.
- Overview of the Subsidiary Subject to Change
(1) Name | Nippon Sanso Homecare España, S.L.U. |
(2) Location | Passeig del Ferrocarril, 369, P. I. Camí Ral, 08860 Castelldefels, Barcelona, Spain |
(3) Name and title of representative | Director Justin Corcho(Mr.) |
(4) Line of business | Home healthcare services business |
(5) Capital | EUR 35.7 million |
(6) Establishment | February 2009 |
(7) Major shareholder(s) and ownership | Oximesa S.L.U. 100% |
percentage | |||
(8) Relationship between the listed company and the relevant company | Capital Relationship | The company is a 100% owned subsidiary of Oximesa S.L.U., which is NSHD's European subsidiary. | |
Personnel Relationship | None | ||
Business Relationship | None | ||
(9) Operating results and financial status of the relevant company for the last three years | |||
Fiscal Year | Fiscal Year ended December 2022 | Fiscal Year ended December 2023 | Fiscal Year ended June December 2024 |
Net Assets | 12 million EUR | 14 million EUR | 36 million EUR |
Total Assets | 47 million EUR | 61 million EUR | 59 million EUR |
Revenue | 33 million EUR | 37 million EUR | 40 million EUR |
Operating Profit | 4 million EUR | 3 million EUR | 3 million EUR |
Net Profit | 3 million EUR | 2 million EUR | 2 million EUR |
-
Date of Transfer
March 3, 2026
- Future Outlook
The impact of this matter has been incorporated into the full-year consolidated earnings forecast for the fiscal year ending March 2026, announced on February 5, 2026.